BRPI0612431A2 - composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c - Google Patents

composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c

Info

Publication number
BRPI0612431A2
BRPI0612431A2 BRPI0612431-3A BRPI0612431A BRPI0612431A2 BR PI0612431 A2 BRPI0612431 A2 BR PI0612431A2 BR PI0612431 A BRPI0612431 A BR PI0612431A BR PI0612431 A2 BRPI0612431 A2 BR PI0612431A2
Authority
BR
Brazil
Prior art keywords
cupredoxin
cytochrome
methods
compositions
treatment
Prior art date
Application number
BRPI0612431-3A
Other languages
English (en)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Tohru Yamada
Anita Chaudhari
Arsenio Fialho
Chang Soo Hong
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BRPI0612431A2 publication Critical patent/BRPI0612431A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA O TRATAMENTO DA INFECÇçO DO HIV. Mais precisamente a presente invenção se refere à cupredoxina, especificamente à aruzina de Pseudomonas aeruginosa, e/ou Pseudomonas aeruginosa citocromo c551, bem como seu uso na inibição da infecção viral, e em especial, infecção das células de mamíferos pelo Vírus da Imunodeficiência Humana (HIV). A invenção também se refere às variantes e derivados da cupredoxina e do citocromo e que conservam a capacidade de inibir a infecção viral, em especial pelo Vírus da Imunodeficiência Humana (HIV). A invenção também se refere aos métodos de pesquisa para o estudo das infecções virais e bacterianas em células de mamíferos.
BRPI0612431-3A 2005-05-20 2006-05-19 composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c BRPI0612431A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68283305P 2005-05-20 2005-05-20
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US78086806P 2006-03-10 2006-03-10
PCT/US2006/019565 WO2006127514A2 (en) 2005-05-20 2006-05-19 Compositions and methods for treating hiv infection with cupredoxin and cytochrome c

Publications (1)

Publication Number Publication Date
BRPI0612431A2 true BRPI0612431A2 (pt) 2009-02-10

Family

ID=37452656

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612431-3A BRPI0612431A2 (pt) 2005-05-20 2006-05-19 composiÇÕes e mÉtodos para o tratamento da infecÇço hiv com cupredoxina e citocromo c

Country Status (10)

Country Link
EP (1) EP1883650A4 (pt)
JP (1) JP2008545398A (pt)
KR (1) KR20080024124A (pt)
AU (1) AU2006251644A1 (pt)
BR (1) BRPI0612431A2 (pt)
CA (1) CA2608398A1 (pt)
IL (1) IL187160A0 (pt)
MX (1) MX2007014599A (pt)
NO (1) NO20076389L (pt)
WO (1) WO2006127514A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
WO2007012004A2 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
WO2007024368A2 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
CN101600728A (zh) * 2006-12-04 2009-12-09 伊利诺斯大学理事会 使用铜氧还蛋白和富含CpG的DNA治疗癌症的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100955974B1 (ko) * 2001-02-15 2010-05-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
BRPI0612456A2 (pt) * 2005-05-20 2009-02-17 Univ Illinois composiÇÕes e mÉtodos para o tratamento da malÁria com cupredoxina e citocromo

Also Published As

Publication number Publication date
IL187160A0 (en) 2008-02-09
EP1883650A2 (en) 2008-02-06
MX2007014599A (es) 2008-02-07
CA2608398A1 (en) 2006-11-30
WO2006127514A3 (en) 2008-06-26
JP2008545398A (ja) 2008-12-18
AU2006251644A1 (en) 2006-11-30
NO20076389L (no) 2008-02-20
KR20080024124A (ko) 2008-03-17
WO2006127514A2 (en) 2006-11-30
EP1883650A4 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
BR112013028813A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
BR112015014714A2 (pt) compostos carbamoilpiridona policíclicos e seu uso farmacêutico
BR112015003592A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
BRPI0516751A (pt) pirimidinas bicìclicas que inibem hcv
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112014017650A2 (pt) composições e uso de ésteres de forbol
BRPI0815547B8 (pt) composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
BR0315937A (pt) Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112013031021A2 (pt) composições e métodos para a inibição da expressão de gene do vírus da hepatite b'
BR112014012983A2 (pt) derivados de pirrol
BR112014011055A2 (pt) novos derivados de [1,2,3]triazolo[4,5-d]pirimidina
MX2021011107A (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb.
BR112022019206A2 (pt) Tratamento de infecções por coronavírus
BR112013030572A2 (pt) misturas pesticidas compreendendo derivados de isoxazolina
BR112022003046A8 (pt) Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
BR112014014662A2 (pt) uso de derivados de diamina antranílica com substituintes heteroaromáticos e heterocíclicos em combinação com um agente de controle biológico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.